Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2022-05-03 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2022-05-03 English
Terms of availability of prospectuses
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the establishment of an At-The-Market ("ATM") program for the offering and sale of American Depositary Shares (ADSs) up to a gross amount of $75 million. This activity directly relates to the company raising capital through the issuance of new shares/securities. This falls squarely under the definition of 'Capital/Financing Update' (CAP). Although it mentions future shareholder votes regarding capital increases, the primary subject is the immediate establishment and terms of the financing program.
2022-05-03 English
Modalités de mise à disposition de prospectus
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated May 3, 2022, announcing that Innate Pharma has established an At-The-Market ("ATM") program on NASDAQ, involving the filing of a "prospectus supplement" with the SEC for the potential issuance of up to $75 million in American Depositary Shares (ADSs). The text explicitly discusses the mechanics of capital raising, the use of proceeds for R&D, references to SEC filings (Form F-3), and the legal basis for capital increases under French commercial and monetary codes. This activity directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not an Earnings Release (ER) as it focuses on financing, nor is it a full Annual Report (10-K) or Interim Report (IR).
2022-05-03 French
6-K
Foreign Filer Report
2022-05-03 English
424B5
Prospectus
2022-05-03 English
6-K
Foreign Filer Report
2022-05-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.